Digest Network Come funziona
Network
/
Società
DB
Non verificato

DBV Technologies S.A.

Di cosa scriviamo

BiotecnologiaPolitica Internazionale

91 comunicati stampa

Guarda tutti i comunicati
16/01/2026
Biotecnologia
Politica Internazionale
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
16/01/2026
Biotecnologia
Politica Internazionale
DBV Technologies annonce avoir reçu un produit brut de 166,7 millions d'euros suite à l'exercice intégral des Bons de Souscription (BS) issus des ABSAs et des BS issus des PFW-BS-PFW émis dans le cadre de son financement de mars 2025
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
12/01/2026
Biotecnologia
Politica Internazionale
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 décembre 2025
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
12/01/2026
Biotecnologia
Politica Internazionale
Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
07/01/2026
Biotecnologia
Politica Internazionale
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
07/01/2026
Biotecnologia
Politica Internazionale
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
05/01/2026
Biotecnologia
Politica Internazionale
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 décembre 2025
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
05/01/2026
Biotecnologia
Politica Internazionale
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
16/12/2025
Biotecnologia
Politica Internazionale
DBV Technologies annonce des résultats préliminaires positifs dans l’étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques à l’arachide
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
16/12/2025
Biotecnologia
Politica Internazionale
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0